Medicines List

Description

Selegiline is a selective inhibitor of brain monoamine oxidase (MAO) type B. MAO-B is involved in enzymatic degradation of the endogenous dopamine and  also in Levodopa’ degradation.

Indications

-  Treatment of Parkinson’s disease, or symptomatic Parkinsonism

Jamax is indicated for treatment of Parkinson’s disease, or symptomatic Parkinsonism, alone or in combination with Levodopa, with or without enzyme inhibitor. In the early stages of the Parkinson’s disease Jamax can be used to delay the administration of Levodopa (with or without decarboxylase inhibitor).

Sufficient results are obtained when administering Jamax alone in the early or mid stages of the disease.

The administration of Jamax relives but does not prevent the development of symptoms and does not improve the mobility without additional administration of Levodopa (with or without decarboxylase inhibitor).

Jamax may be applied in the late stages of the disease to increase the effectiveness of Levodopa, especially in patients who are suffering from on / off or other symptoms that may be associated with a reduction in the effectiveness of treatment.

Subject to medical prescription

Pharmaceutical form: 5 mg x 30 tablets

NHIF code: NF 367          ICD: G20

Description

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) taken to reduce inflammation and as an analgesic reducing pain in conditions such as arthritis or acute injury.

Indications

- Inflammatory and degenerative forms of rheumatism: chronic polyarthritis, juvenile chronic polyarthritis, arthroses (including spondylarthroses)

– Periarthritis humeroscapularis

- Acute gout attacks

- Painful postoperative and post-traumatic inflammation and swelling, e.g. as a result of dental or orthopedic surgery

Gastro-resistant  tablets Diclofenac are not suitable for acute indications or if necessary the rapid removal of pain.

Subject to medical prescription

Pharmaceutical form: 50 mg x 30 gastro-resistant tablets

NHIF code: MF 117

ICD: G54.0; G54.1; G54.2; G54.3; G54.4; G54.5; G54.6; M05.0, M05.1, M05.2, M05.3, M05.8; M07.1; M07.2; M07.3; M08.1, M08.2, M08.3, M08.4; M30.0; M31.3; M32.1, M32.8, M33.0, M33.1, M33.2, М34.0, M34.1, M34.2, М45.0

Description

Irinotecan is a cytostatic inhibitor of topoisomerase I, semi-synthetic derivative of kamptotecin. It is an antineoplastic agent that acts as a specific inhibitor of DNA topoisomerase I, including lesions of one strand of DNA that blocks replication fork DNA. Besides anticancer activity of Irinotecan, his most important pharmacological effect is blocking acetylcholinesterase.

Indications

Irinotecan is indicated for treatment of patients with advanced colorectal cancer:

-         in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.

-         as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

Subject to medical prescription

Pharmaceutical form: 20 mg/ml concentrate for solution for infusion

Description

Metamizole sodium is a nonsteroidal anti-inflammatory drug (NSAID), the group of pirazolones. It has analgesic (painkiller) and antipyretic (temperature decreasing) effect, with a weaker anti-inflammatory activity and mild antispasmodic action.

Indications

-         Pain with various origin and intensity when other agents are ineffective or contraindicated – headache, tootache, joint and muscle and inflammation; posttraumatic and postoperative pain; renal and biliary ducts, dyskinesia; upper respiratory tract inflammation of microbial or viral origin; cancer pain with WBC monitoring. In the internationally accepted cancer pain relief regimen.

Metamizole is recommended as the “last but one step” prior to administration of narcotic analgesics.

-          Elevation of high body temperature

Subject to non-medical prescription

Pharmaceutical form: 500 mg x 10 tablets